NASDAQ:ACIU
AC Immune SA Stock News
$3.18
-0.230 (-6.74%)
At Close: May 17, 2024
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
08:25am, Wednesday, 29'th Jun 2022 Benzinga
Gainers
Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
AC Immune Holds Annual General Meeting of Shareholders
08:30pm, Friday, 24'th Jun 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today a
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
12:31pm, Friday, 17'th Jun 2022 Zacks Investment Research
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
In a tough, post-Fed market, strategist finds opportunity knocking in a couple of this year's hottest sectors
12:16pm, Thursday, 16'th Jun 2022 MarketWatch
A tough U.S. session is setting up, and one strategist has sifted through the market rubble to find opportunities.
AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals
06:39am, Thursday, 16'th Jun 2022
Shares of biotech AC Immune SA ACIU, -9.21% slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer's disease failed to slow or prevent cognitive decline in
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
05:00am, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease
AC Immune to Present at the 2022 Jefferies Healthcare Conference
11:30am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today an
AC Immune to Present at the 2022 Jefferies Healthcare Conference
07:30am, Tuesday, 31'st May 2022
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno
AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology
03:00pm, Monday, 09'th May 2022 GlobeNewswire Inc.
First study of an anti-Abeta vaccine in people living with Down syndrome (DS)
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
11:30am, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Two clinical readouts delivered in Q1; five more expected by year-end
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
11:55am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
07:55am, Wednesday, 27'th Apr 2022
LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today an
AC Immune Reports Changes to Senior Management
11:30am, Friday, 08'th Apr 2022 GlobeNewswire Inc.
Howard Donovan appointed Chief HR Officer, joins executive committee
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
11:30am, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
Seven clinical data readouts expected in 2022Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H
AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases
11:30am, Monday, 21'st Mar 2022 GlobeNewswire Inc.
Webinar to take place on Tuesday, March 29th at 10:00 AM ET / 4:00 PM CET Webinar to take place on Tuesday, March 29th at 10:00 AM ET / 4:00 PM CET
